I get your point, but please understand that this is a bit different then marketing Nuplazid where you have many tens of thousands or more of patients vs 4,500 patients.

 

Those with rare diseases typically are well connected.  It is very unlikely that any of those with Rett are not already familiar with Acadia's RETT drug.

 

I would also add that I respect Tim's feedback with regards to the costs, but like I said I believe Acadia has already hired most of the team they require for DayBue sales.  The cost to manufacture this drug is likely a tiny fraction of the cost.

 

One good point is how long will it take the insurance companies, especially Medicare and Medicaid will agree to pay for the drug.  This will definitely impact when we begin to see revenues from the drug.